CAAS Capital Management’s MaxCyte MXCT Stock Holding History

CAAS Capital Management’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-10,000	Closed	-$122K	–	984
2021 Q3	$122K	Buy	+10,000	New	+$151K	﹤0.01%	773

Other funds holding MXCT

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

DCP

D1 Capital Partners New York $11.2B AUM 15.78% 1-Year Est. Return

Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

RGI

River Global Investors London, United Kingdom $515M AUM 24.86% 1-Year Est. Return

NTCM

Nine Ten Capital Management Chicago, Illinois $315M AUM 62.95% 1-Year Est. Return

CAAS Capital Management's MXCT Position: Q4 2021 in Review

CAAS Capital Management sold out of MaxCyte (MXCT) in Q4 2021, closing a stake of 10,000 shares — an estimated $122K sold.

CAAS Capital Management first reported a position in MXCT in Q3 2021 and held it in 1 quarter. The position peaked at $122K in Q3 2021. 103 funds tracked by Wall St. Rank hold MXCT as of Q4 2021.

CAAS Capital Management reported no remaining MaxCyte position as of Q4 2021 after selling out during the quarter.
CAAS Capital Management sold 10,000 MaxCyte shares in Q4 2021, an estimated $122K.
CAAS Capital Management first reported a position in MaxCyte in Q3 2021 and held it in 1 quarter.
CAAS Capital Management's MaxCyte position peaked at $122K in Q3 2021.
103 funds tracked by Wall St. Rank held MaxCyte as of Q4 2021.

Based on CAAS Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.